These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 36516090

  • 21. Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing.
    Woodley DT, Remington J, Huang Y, Hou Y, Li W, Keene DR, Chen M.
    Mol Ther; 2007 Mar; 15(3):628-35. PubMed ID: 17245357
    [Abstract] [Full Text] [Related]

  • 22. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.
    Venugopal SS, Yan W, Frew JW, Cohn HI, Rhodes LM, Tran K, Melbourne W, Nelson JA, Sturm M, Fogarty J, Marinkovich MP, Igawa S, Ishida-Yamamoto A, Murrell DF.
    J Am Acad Dermatol; 2013 Dec; 69(6):898-908.e7. PubMed ID: 24075228
    [Abstract] [Full Text] [Related]

  • 23. Current Treatment Landscape for Dystrophic Epidermolysis Bullosa: From Surgical Management to Emerging Gene Therapies and Novel Skin Grafts.
    Villavisanis DF, Perrault DP, Kiani SN, Cholok D, Fox PM.
    J Hand Surg Am; 2024 May; 49(5):472-480. PubMed ID: 38085193
    [Abstract] [Full Text] [Related]

  • 24. Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients.
    Lee SE, Lee SJ, Kim SE, Kim K, Cho B, Roh K, Kim SC.
    JCI Insight; 2021 Jan 25; 6(2):. PubMed ID: 33491668
    [Abstract] [Full Text] [Related]

  • 25. Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing.
    Onoufriadis A, Proudfoot LE, Ainali C, Torre D, Papanikolaou M, Rayinda T, Rashidghamat E, Danarti R, Mellerio JE, Ma'ayan A, McGrath JA.
    Exp Dermatol; 2022 Mar 25; 31(3):420-426. PubMed ID: 34694680
    [Abstract] [Full Text] [Related]

  • 26. Mild recessive dystrophic epidermolysis bullosa associated with two compound heterozygous COL7A1 mutations.
    von Bartenwerffer W, Has C, Arin MJ, Tantcheva-Poór I, Kreuter A, Kremer K, Arshah T, Hoffmann M, Eming SA, Kohlhase J, Krieg T, Bruckner-Tuderman L, Hartmann K.
    Eur J Dermatol; 2011 Mar 25; 21(2):170-2. PubMed ID: 21382783
    [Abstract] [Full Text] [Related]

  • 27. Rat model for dominant dystrophic epidermolysis bullosa: glycine substitution reduces collagen VII stability and shows gene-dosage effect.
    Nyström A, Buttgereit J, Bader M, Shmidt T, Ozcelik C, Hausser I, Bruckner-Tuderman L, Kern JS.
    PLoS One; 2013 Mar 25; 8(5):e64243. PubMed ID: 23717576
    [Abstract] [Full Text] [Related]

  • 28. Natural gene therapy in dystrophic epidermolysis bullosa.
    van den Akker PC, Nijenhuis M, Meijer G, Hofstra RM, Jonkman MF, Pasmooij AM.
    Arch Dermatol; 2012 Feb 25; 148(2):213-6. PubMed ID: 22004882
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Development of Minicircle Vectors Encoding COL7A1 Gene with Human Promoters for Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa.
    Wang X, Alshehri F, Manzanares D, Li Y, He Z, Qiu B, Zeng M, A S, Lara-Sáez I, Wang W.
    Int J Mol Sci; 2021 Nov 26; 22(23):. PubMed ID: 34884578
    [Abstract] [Full Text] [Related]

  • 32. Canakinumab in recessive dystrophic epidermolysis bullosa: a novel unexpected weapon for non-healing wounds?
    Annicchiarico G, Lopalco G, Morgese MG, Cantarini L, Iannone F.
    Clin Exp Rheumatol; 2016 Nov 26; 34(5):961-962. PubMed ID: 26885873
    [No Abstract] [Full Text] [Related]

  • 33. Lipid Nanoparticles Efficiently Deliver the Base Editor ABE8e for COL7A1 Correction in Dystrophic Epidermolysis Bullosa Fibroblasts In Vitro.
    Guri-Lamce I, Alrokh Y, Graham C, Maeshima R, Rognoni E, Caley M, Łaczmański Ł, Hart SL, McGrath JA, Jacków-Malinowska J.
    J Invest Dermatol; 2024 Oct 26; 144(10):2314-2317.e3. PubMed ID: 38583743
    [No Abstract] [Full Text] [Related]

  • 34. Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa.
    Dang N, Murrell DF.
    Exp Dermatol; 2008 Jul 26; 17(7):553-68. PubMed ID: 18558993
    [Abstract] [Full Text] [Related]

  • 35. Identical COL71A1 heterozygous mutations resulting in different dystrophic epidermolysis bullosa phenotypes.
    Knöpfel N, Noguera-Morel L, Hernández-Martin A, García-Martin A, García M, Mencía Á, Pedrero RM, de Lucas R, Escámez MJ, Torrelo A.
    Pediatr Dermatol; 2018 Mar 26; 35(2):e94-e98. PubMed ID: 29272047
    [Abstract] [Full Text] [Related]

  • 36. Purified type I collagen wound matrix improves chronic wound healing in patients with recessive dystrophic epidermolysis bullosa.
    Gorell ES, Leung TH, Khuu P, Lane AT.
    Pediatr Dermatol; 2015 Mar 26; 32(2):220-5. PubMed ID: 25557742
    [Abstract] [Full Text] [Related]

  • 37. Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa.
    Lwin SM, Syed F, Di WL, Kadiyirire T, Liu L, Guy A, Petrova A, Abdul-Wahab A, Reid F, Phillips R, Elstad M, Georgiadis C, Aristodemou S, Lovell PA, McMillan JR, Mee J, Miskinyte S, Titeux M, Ozoemena L, Pramanik R, Serrano S, Rowles R, Maurin C, Orrin E, Martinez-Queipo M, Rashidghamat E, Tziotzios C, Onoufriadis A, Chen M, Chan L, Farzaneh F, Del Rio M, Tolar J, Bauer JW, Larcher F, Antoniou MN, Hovnanian A, Thrasher AJ, Mellerio JE, Qasim W, McGrath JA.
    JCI Insight; 2019 Jun 06; 4(11):. PubMed ID: 31167965
    [Abstract] [Full Text] [Related]

  • 38. Topical application of recombinant type VII collagen incorporates into the dermal-epidermal junction and promotes wound closure.
    Wang X, Ghasri P, Amir M, Hwang B, Hou Y, Khalili M, Khilili M, Lin A, Keene D, Uitto J, Woodley DT, Chen M.
    Mol Ther; 2013 Jul 06; 21(7):1335-44. PubMed ID: 23670575
    [Abstract] [Full Text] [Related]

  • 39. Systemic Collagen VII Replacement Therapy for Advanced Recessive Dystrophic Epidermolysis Bullosa.
    Gretzmeier C, Pin D, Kern JS, Chen M, Woodley DT, Bruckner-Tuderman L, de Souza MP, Nyström A.
    J Invest Dermatol; 2022 Apr 06; 142(4):1094-1102.e3. PubMed ID: 34606885
    [Abstract] [Full Text] [Related]

  • 40. Type VII collagen: the anchoring fibril protein at fault in dystrophic epidermolysis bullosa.
    Chung HJ, Uitto J.
    Dermatol Clin; 2010 Jan 06; 28(1):93-105. PubMed ID: 19945621
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.